Articles tagged with Cancer Cells
Blocking the activation of Stat5 in prostate cancer cells triggers extensive cell death, providing a new targeted therapeutic approach to manage cancer growth and metastasis. Prostate cancer is the second leading cause of cancer death in men, with approximately 220,900 new cases expected in the US in 2003.
Researchers have developed microgel polymer beads that can be engineered to break apart in acidic conditions, releasing vaccine antigens on the surface of immune cells. This technique avoids destroying protein antigens with stomach acids, making it a promising approach for future vaccines and gene therapy.
Researchers found that a bacterial enzyme, peroxiredoxin, controls the balance of hydrogen peroxide in cells. The enzyme regulates hydrogen peroxide levels to prevent damage while allowing it to signal important cellular processes.
Researchers found that ovarian cancer cells produce collagen VI, which remodels their environment to make them more resistant to chemotherapy. This could lead to new therapeutic interventions to overcome chemotherapy resistance and improve survival rates for women with ovarian cancer.
Researchers have developed a novel screening technique that quickly identifies chemical compounds active only against certain cancer-causing genes and proteins. This approach opens the door to custom-tailoring chemotherapy and may lead to more effective treatments for specific types of cancer.
Researchers at Virginia Tech have designed a new class of molecules that can bind to and stop replication of DNA when triggered by light. The complex molecules, developed by Professor Karen Brewer's group, have demonstrated the ability to kill cells in the presence of light.
A new study reveals that ATR kinase plays a crucial role in maintaining genome integrity by regulating cell cycle checkpoints and preventing DNA damage. The study shows that ATR is essential for ensuring cells leave the cell cycle without DNA damage, which can lead to diseases such as cancer.
Researchers at Georgetown University Medical Center found that malfunctioning beta-spectrin genes cause defects in embryonic development and interfere with TGF-beta functions, which are crucial for growth and cancer progression. This discovery has important implications for human disease research and treatment.
A recent study found that a rare genetic disease is caused by the shortening of telomeres, leading to premature aging symptoms like hair loss and slow wound healing. The researchers discovered that telomere dysfunction disrupts chromosome function, resulting in cellular chaos and organ failure.
Researchers found that cancer cells can migrate through protein matrices by reverting to a more rounded shape, allowing them to continue moving even when inhibitors are present. This 'salvage' pathway could be targeted by new drugs to combat cancer spread.
A breakthrough discovery by Saint Louis University researchers reveals how the protein Bre1 functions in normal cells, shedding light on its role in cancer development. The study suggests that understanding this protein's regulation of gene expression could lead to new ways to block cancer-causing pathways.
Researchers identified a protein called CUGBP2 that regulates the production of COX-2, a key culprit in arthritis and cancer. When CUGBP2 levels are high, it triggers cancer cell death by inhibiting COX-2 production.
New tri-metallic supra-molecules can be positioned in exact parts of cancer cells and excited by therapeutic light to kill diseased cells. The system enables precise targeting, reducing side effects of chemotherapy.
Cells utilize an enzyme called the proteasome to remove unnecessary proteins. The study found that the proteasome can independently degrade substrates involved in Parkinson's disease and some types of cancer, producing fragments reminiscent of pathological deposits in Parkinson's patients.
Scientists discovered that SNF5 is a tumor suppressor gene responsible for malignant rhabdoid tumors, a rare and aggressive childhood cancer. The study used a novel knockout technique to create mice with reversible, inverting conditional SNF5 genes, which developed cancers quickly.
Researchers found that overexpressed LPAAT-beta is highly tumorigenic and causes cancer cells to die when inhibited. The small molecule inhibitors induce apoptosis in various tumor cell lines, including lung and colon cancers.
Scientists at Stanford University have created synthetic DNA nanocircles that can lengthen telomeres in test tube cells, a key factor in determining cell lifespan. This breakthrough could lead to the development of new methods for studying aging and cancer, as well as alternative approaches to transplantation medicine.
Researchers from the University of Pittsburgh found that KSHV, a known carcinogenic virus, inhibits immune function and causes cancerous cells to grow through a hormone-like substance called vIL-6. This discovery reveals an overlap between the immune system and tumor suppressor pathways targeted by KSHV.
Researchers at Johns Hopkins University have identified a complex signaling pathway that regulates gene activity in living cells. The discovery reveals that the timing of signal transmission plays a critical role in determining which genes are activated, and could lead to the development of new medications targeting cancer cells.
Researchers at UW-Madison have identified the PIPKI?661 enzyme as a promising target for preventing cancer cells from metastasizing. By inhibiting this enzyme, cancer cells' ability to migrate to other parts of the body can be blocked.
Researchers designed a DNA vaccine that stimulates the immune system to recognize and attack proliferating blood vessels in tumors, depriving them of oxygen and nutrients. The vaccine has shown promise in preventing effective angiogenesis and inhibiting tumor growth, offering potential for novel cancer therapies.
A new strategy in cancer treatment involves using genetic information to guide drug delivery, allowing for more targeted and efficient treatments. The approach uses nucleic acid-triggered catalytic drug release, recognizing and responding to unique cancerous sequences to deliver potent anticancer drugs.
Gene Network Sciences will use the federal grant to learn how pharmaceuticals work against cancer cells, creating computer models to identify nontoxic drug targets. The company aims to make drug-discovery more predictable for pharmaceutical and biotech companies with its new technology.
A study published in Immunity reveals that the MEF protein plays a critical role in the development and function of natural killer cells, which can recognize and kill cancer cells. The findings provide a new target for therapeutic interventions, potentially improving bone marrow transplant strategies.
Researchers at the Norwegian Cancer Society have discovered that certain types of fish fat contain compounds with anti-cancer properties. The study suggests that these compounds may be used to develop new treatments for various types of cancer.
Researchers at Memorial Sloan Kettering Cancer Center discovered that cancer cells containing high levels of Myc protein cannot activate p21 gene production, leading to cell death. The study's findings suggest a potential strategy to increase chemotherapy effectiveness by favoring apoptosis over citostasis.
Research highlights increased cervical cancer risk in smokers, while ovarian tumors with BRCA2 mutations also commonly have BRCA1 mutations. A potential therapeutic approach for eliminating malignant urothelial cells is also explored through CD40 ligation.
Researchers at UNC Chapel Hill used nuclear magnetic resonance spectroscopy to study the effects of crowded environments on protein shape. They found that intrinsically unstructured proteins exhibit a definite folded-up shape when inside cells, unlike their apparent lack of structure in water solutions.
Researchers have isolated a key component of cell death signals that can be targeted to prevent cancer growth. By understanding how these signals interact, scientists hope to develop new anti-cancer therapies.
Cancer cells have evolved to continually activate telomerase, keeping telomeres intact and enabling rapid division. Researchers at UC Berkeley are now searching for proteins and signals involved in telomerase shuttling around the cell nucleus to develop new therapeutic strategies.
Researchers at University of Illinois Chicago have discovered a way to render cancer cells more susceptible to immunological attacks and chemotherapy. By inserting the E1A gene into malignant cells, they can prevent tumor cells from blocking immune defenses, paving the way for new treatments.
Researchers at Hebrew University have developed a novel technique that uses an engineered virus to induce cancer cells to activate PKR protein, causing them to self-destruct. This innovative approach has shown promising results in halting the spread of brain tumors and offers a new direction for cancer treatment.
Researchers found that Clb2 is the real trigger for yeast cell division, contradicting previous findings on Clb5. This discovery has implications for treating cancer, as it reveals a new way to understand the cell cycle mechanism.
The study found that exposure to ELF-EMF alone did not affect cell division, but combining it with ionising radiation caused cells to slow down at checkpoints. This suggests ELF-EMF may enable damaged cells to divide further, increasing cancer risk.
Researchers have developed a cancer vaccine that targets telomerase, a protein responsible for cancer cells' unlimited division. The vaccine has shown promise in encouraging an immune response in patients with pancreatic cancer, leading to longer survival rates.
This study found that paclitaxel- and carboplatin-based regimens can prolong survival of patients with advanced non-small cell lung cancer, with two-year survival rates similar to those achieved at one year with best supportive care. However, three-drug regimens were slightly more toxic and did not provide additional benefits.
Researchers John Tyson and Bela Novak are developing mathematical models of yeast cell growth and division to better understand the molecular mechanisms controlling cell behavior. Their work aims to extrapolate findings from yeast cells to humans, with potential implications for cancer research and other cell-based diseases.
Researchers found that abnormal E-cadherin presence in cervical lesions can prevent abnormal cells from being collected during testing. This could explain why four in 10 Pap smear results come back negative despite biopsy findings showing abnormalities.
Researchers at the University of Toronto have identified a protein called SSPase that plays a critical role in regulating natural killer cells, which attack foreign or mutated cells. The discovery provides insights into how the immune system works and how viruses and cancer try to evade it.
A new clinical trial, led by Scott Waldman, aims to determine if a test for the protein guanylyl cyclase C can accurately diagnose colorectal cancer spread. The test may improve diagnoses and treatment outcomes by detecting tiny amounts of cancer in lymph nodes.
A new diagnostic faecal test detected MCM2-positive cells in 37 of 40 patients known to have colorectal cancer, but not in healthy individuals. The findings suggest that the test could be suitable for population screening, either alone or in combination with other tests.
Researchers at the University of Illinois Chicago have discovered a signaling mechanism in yeast cells that controls cell growth and differentiation, with potential implications for cancer treatment. The study found that pheromone triggers cells to stop dividing and orient their growth toward the source of pheromone.
Researchers at Rockefeller University have discovered that the 'Reaper' protein triggers programmed cell death by instructing a fly cell's principal guard protein, DIAP1, to self-destruct. This finding may lead to novel strategies for targeting immortal cancer cells without harming healthy cells.
The study found patients who received the high-dose regimen had significantly longer overall and disease-free survival rates than those who received a lower dose. The company plans to initiate a Phase III trial of GVAX prostate cancer vaccine in the first half of 2003.
Researchers Dr. Stella Pelengaris and Dr. Mike Khan found that a single protein, c-Myc, causes faulty cell growth leading to cancer. Their study reveals a simplified model of cancer development, offering new optimism in developing effective treatments.
Imatinib mesylate, a drug used to treat leukemia, has shown remarkable success in reducing eosinophil levels in people with hypereosinophilic syndrome (HES), a difficult-to-treat inflammatory disease. Four of five patients studied experienced complete elimination of symptoms.
Researchers found celecoxib induces cell death without blocking COX-2 enzyme. Alternate mechanism involves decreased phosphorylation of Akt and ERK2 proteins. Newer generations of COX-2 inhibitors may be safer and more effective for colon cancer treatment.
Scientists have developed a new 'gene silencing' strategy using short hairpin RNAs (shRNAs) that can efficiently silence specific genes in mammalian cells. This technique has the potential to revolutionize gene function exploration and could lead to targeted therapies for cancer, AIDS, and other diseases.
Researchers have synthesized peptide mimics that may inhibit Pin1's action, which regulates cell division. The goal is to develop new anticancer therapies by targeting the cell-cycle-regulating enzyme Pin1.
Researchers at Stanford University Medical Center have developed a novel approach to fighting cancer using a modified cold virus that targets cancer cells while leaving normal cells unharmed. In a phase I study, 28 patients who received the highest dose of the virus survived for nearly a year and saw significant tumor shrinkage.
Aging cells retire when their telomeres become too short to function, according to a new Rockefeller University study. The researchers found that protein TRF2 helps critically short telomeres function better, allowing old cells to live longer.
Robert Eisenman, a leading oncogene expert, has made significant contributions to understanding how normal cells become cancerous and impacted studies of AIDS and other diseases. He will receive the award at the AACR annual meeting in San Francisco.
Researchers have created a virtual cell model to study cell motion, driven by a single protein that changes shape in response to pH levels. This model has potential implications for understanding various diseases, including cancer, heart disease, and wound healing.
A team of USC researchers has identified the key role of a previously unknown protein, Artemis, in repairing double-stranded DNA breaks. They found that oxygen causes chromosomal breaks due to oxidative free radicals, leading to genetic information loss.
Researchers at Vanderbilt University Medical Center have identified a new protein called Interleukin 24 (IL-24) that is expressed in colon cancer cells and promotes cell growth or prevents cell death. The discovery could lead to the development of molecules to interrupt an autocrine loop, potentially fueling tumor growth.
A study by Prof. Kerem and Asaf Hellman found that chemotherapy drugs can cause chromosomes to break at specific regions, known as fragile sites, potentially leading to cancer growth. The research creates a better understanding of how cancer drugs work, paving the way for more effective treatments.
Researchers found sulforaphane's phase 2 enzymes protect cells against oxidants for up to three days, preventing damage from cancer, retinal degeneration, and other conditions. Eating large quantities of vegetables, especially cruciferous ones, helps fight disease by increasing antioxidant defenses.
Researchers used molecular scissors to alter the sugar coats of cancer cells, promoting tumor growth with one fragment and inhibiting it with another. This discovery could lead to targeted cancer treatments by exploiting the biological balancing act between different sugar fragments and signaling molecules.
Researchers at the Fred Hutchinson Cancer Research Center have developed a new cell-based approach for anticancer drug discovery, which identified 39 new compounds selective for yeast cells with faulty DNA repair enzymes. This approach is adaptable to high-throughput screening methods and complements target-based screening, potentially...
A prospective population study found that HIV-1-positive women are 16 times more likely to develop vulvovaginal or perianal lesions than HIV-1-negative women. The study suggests that HIV-1-positive women should have a thorough inspection of the vulva and perianal region during gynaecological examination.